262 related articles for article (PubMed ID: 33729654)
21. Evaluation of cytoreductive efficacy of vincristine, cyclophosphamide, and Doxorubicin in dogs with lymphoma by measuring the number of neoplastic lymphoid cells with real-time polymerase chain reaction.
Sato M; Yamazaki J; Goto-Koshino Y; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
J Vet Intern Med; 2011; 25(2):285-91. PubMed ID: 21314729
[TBL] [Abstract][Full Text] [Related]
22. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of baseline absolute lymphocyte concentration and neutrophil/lymphocyte ratio in dogs with newly diagnosed multi-centric lymphoma.
Mutz M; Boudreaux B; Kearney M; Stroda K; Gaunt S; Shiomitsu K
Vet Comp Oncol; 2015 Dec; 13(4):337-47. PubMed ID: 23786518
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma.
Wang SL; Lee JJ; Liao AT
Vet J; 2015 Jul; 205(1):69-73. PubMed ID: 26004824
[TBL] [Abstract][Full Text] [Related]
25. A comparison of 12- and 19-week CHOP protocols using non-randomized, contemporaneous controls.
Vos N; Pellin M; Vail DM
Vet Comp Oncol; 2019 Sep; 17(3):276-284. PubMed ID: 31140707
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma.
Myers NC; Moore AS; Rand WM; Gliatto J; Cotter SM
J Vet Intern Med; 1997; 11(6):333-9. PubMed ID: 9470157
[TBL] [Abstract][Full Text] [Related]
27. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
28. Effect of proteasome inhibitors on canine lymphoma cell response to CHOP chemotherapy in vitro.
Prevedel NE; Mee MW; Wood GA; Coomber BL
Vet Comp Oncol; 2024 Mar; 22(1):96-105. PubMed ID: 38237918
[TBL] [Abstract][Full Text] [Related]
29. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
[TBL] [Abstract][Full Text] [Related]
30. Geographical differences in survival of dogs with non-Hodgkin lymphoma treated with a CHOP based chemotherapy protocol.
Wilson-Robles H; Budke CM; Miller T; Dervisis N; Novosad A; Wright Z; Thamm DH; Vickery K; Burgess K; Childress M; Lori J; Saba C; Rau S; Silver M; Post G; Reeds K; Gillings S; Schleis S; Stein T; Brugmann B; DeRegis C; Smrkovski O; Lawrence J; Laver T
Vet Comp Oncol; 2017 Dec; 15(4):1564-1571. PubMed ID: 28419683
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of CD25 expression in dogs with a noninvasive diagnosis of B-cell lymphoma treated with CHOP chemotherapy.
Sheng R; Clarke D; Laver T; Meichner K; Northrup N; Tarigo J
Vet Comp Oncol; 2023 Mar; 21(1):28-35. PubMed ID: 36111442
[TBL] [Abstract][Full Text] [Related]
32. Advances in chemotherapy for large cell lymphoma.
Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
[TBL] [Abstract][Full Text] [Related]
33. Comparison between L-CHOP and an L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in dogs.
Rassnick KM; Bailey DB; Malone EK; Intile JL; Kiselow MA; Flory AB; Barlow LL; Balkman CE; Barnard SM; Waite AH
Vet Comp Oncol; 2010 Dec; 8(4):243-53. PubMed ID: 21062406
[TBL] [Abstract][Full Text] [Related]
34. Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma.
Saba CF; Thamm DH; Vail DM
J Vet Intern Med; 2007; 21(1):127-32. PubMed ID: 17338160
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA profiling in canine multicentric lymphoma.
Craig KKL; Wood GA; Keller SM; Mutsaers AJ; Wood RD
PLoS One; 2019; 14(12):e0226357. PubMed ID: 31826004
[TBL] [Abstract][Full Text] [Related]
36. Mechlorethamine, vincristine, melphalan and prednisone (MOMP) for the treatment of relapsed lymphoma in dogs.
Back AR; Schleis SE; Smrkovski OA; Lee J; Smith AN; Phillips JC
Vet Comp Oncol; 2015 Dec; 13(4):398-408. PubMed ID: 23910023
[TBL] [Abstract][Full Text] [Related]
37. Patient characteristics, prognostic factors and outcome of dogs with high-grade primary mediastinal lymphoma.
Moore EL; Vernau W; Rebhun RB; Skorupski KA; Burton JH
Vet Comp Oncol; 2018 Mar; 16(1):E45-E51. PubMed ID: 28660709
[TBL] [Abstract][Full Text] [Related]
38. Construction and validation of a scoring system to predict resistance to chemotherapeutic drugs using gene expression profiles in canine lymphoma.
Tani A; Saegusa Y; Ogawa K; Tomiyasu H; Takeuchi Y; Harada K; Kobayashi T; Setoguchi A; Nakamichi J; Mizuno T; Irie M; Tokita M; Fujita K; Suenaga M; Motegi T; Ohmi A; Goto-Koshino Y; Ohno K; Tsujimoto H
Res Vet Sci; 2021 Jul; 137():208-216. PubMed ID: 34020336
[TBL] [Abstract][Full Text] [Related]
39. Are B-symptoms more reliable prognostic indicators than substage in canine nodal diffuse large B-cell lymphoma.
Škor O; Bicanová L; Wolfesberger B; Fuchs-Baumgartinger A; Ruetgen B; Štěrbová M; Schwendenwein I; Kleiter M
Vet Comp Oncol; 2021 Mar; 19(1):201-208. PubMed ID: 33136315
[TBL] [Abstract][Full Text] [Related]
40. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
